EML4 and non-small cell lung carcinoma: Crizotinib 1 (Figure 2 and Figure 3) is an approved first generation ALK inhibitor (IC50 vs. EML4-ALK = 250–300 nM) [34] used to treat ALK-positive non-small cell lung cancer (NSCLC).